Cancer Genetics and Epigenetics 2024, Vol.12, No.5, 294-305 http://medscipublisher.com/index.php/cge 304 Gomez S., Cox O.L., Walker R.R., Rentia U., Hadley M., Arthofer, E., Diab, N., Grundy E.E., Kanholm T., McDonald J.I., Kobyra J., Palmer E., Noonepalle S., Villagra A., Leitenberg D., Bollard C., Saunthararajah Y., and Chiappinelli K.B., 2022, Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer, Journal for Immunotherapy of Cancer, 10. https://doi.org/10.1136/jitc-2022-004974 PMID: 36343976 PMCID: PMC9644370 He Z.Y., Zhang Y., Yang Y.H., Ma C.C., Wang P., Du W., Li L., Xiang R., Song X.R., Zhao X., Yao S.H., and Wei Y.Q., 2018, In vivo ovarian cancer gene therapy using CRISPR-Cas9, Human Gene Therapy, 29(2): 223-233. https://doi.org/10.1089/hum.2017.209 Huang K.C., Yang J.Z., Ng M.C., Ng S., Welch W., Muto M., and Ng S., 2016, Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells, European Journal of Cancer, 67: 152-163. https://doi.org/10.1016/j.ejca.2016.08.007 Karimian A., Azizian K., Parsian H., Rafieian S., Shafiei-Irannejad V., Kheyrollah M., Yousefi M., Majidinia M., and Yousefi B., 2019, CRISPR-Cas9 technology as a potent molecular tool for gene therapy, Journal of Cellular Physiology, 234(9): 12267-12277. https://doi.org/10.1002/jcp.27972 PMID: 30697727 Kodama M., Kodama T., Newberg J., Copeland N.G., and Jenkins N.A., 2016, Abstract 65: in vivo pooled shRNA library screens identify cancer genes driving epithelial ovarian cancer, Cancer Research, 76(14_Supplement): 65. https://doi.org/10.1158/1538-7445.AM2016-65 Li H.Y., Yang Y., Hong W.Q., Huang M.Y., Wu M., and Zhao X., 2020, Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects, Signal Transduction and Targeted Therapy, 5(1): 1. https://doi.org/10.1038/s41392-019-0089-y PMID: 32296011 PMCID: PMC6946647 Luo S., Wang Y.J., Tao Y.Y., Li S., Wang Z.R., He W., Wang H.X., Wang N., Xu J.W., and Song H.L., 2021, Application in gene editing in ovarian cancer therapy, Cancer Investigation, 40(4): 387-399. https://doi.org/10.1080/07357907.2021.1998521 PMID: 34758691 Naeem M., Majeed S., Hoque M.Z., and Ahmad I., 2020, Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing, Cells, 9: 1608. https://doi.org/10.3390/cells9071608 PMID: 32630835 PMCID: PMC7407193 Panda A., Stein M., Riedlinger G., Bhanot G., and Ganesan S., 2019, Role for immune checkpoint blockade in BRCA2-mutant prostate cancer, Journal of Clinical Oncology, 37(8_Supplement): 59. https://doi.org/10.1200/JCO.2019.37.8_SUPPL.59 Quiñones-Díaz B.I., Reyes-González J.M., Sánchez-Guzmán V., Conde-Del Moral I., Valiyeva F., Santiago-Sánchez G.S., and Vivas-Meji P.E., 2020, MicroRNA-18a-5p suppresses tumor growth via targeting matrix metalloproteinase-3 in cisplatin-resistant ovarian cancer, Frontiers in Oncology, 10: 602670. https://doi.org/10.3389/fonc.2020.602670 PMID: 33392094 PMCID: PMC7774672 Romero-Garcia S., Prado-Garcia H., and Carlos-Reyes Á., 2020, Role of DNA methylation in the resistance to therapy in solid tumors, Frontiers in Oncology, 10: 1152. https://doi.org/10.3389/fonc.2020.01152 PMID: 32850327 PMCID: PMC7426728 Sang X.B., Sun K.X., Wang L.L., Chen S., Wu D.D., and Zhao Y., 2016, Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis, Oncology Reports, 36(6): 3267-3274. https://doi.org/10.3892/or.2016.5164 PMID: 27748937 Schreurs J., Sacchetto C., Colpaert R.M.W., Vitiello L., Rampazzo A., and Calore M., 2021, Recent advances in CRISPR/Cas9-based genome editing tools for cardiac diseases, International Journal of Molecular Sciences, 22(20): 10985. https://doi.org/10.3390/ijms222010985 PMID: 34681646 PMCID: PMC8537312 Tassi R.A., Todeschini P., Siegel E.R., Calza S., Cappella P., Ardighieri L., Cadei M., Bugatti M., Romani C., Bandiera E., Zanotti L., Tassone L., Guarino D., Santonocito C., Capoluongo E.D., Beltrame L., Erba E., Marchini S., D'Incalci M., Donzelli C., Santin A.D., Pecorelli S., Sartori E., Bignotti E., Odicino F., and Ravaggi A., 2017, FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients, Journal of Experimental and Clinical Cancer Research, 36(1): 63. https://doi.org/10.1186/s13046-017-0536-y Vasquez C.A., Cowan Q.T., and Komor A.C., 2020, Base editing in human cells to produce single-nucleotide-variant clonal cell lines, Current Protocols in Molecular Biology, 133 https://doi.org/10.1002/cpmb.129
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==